Brief: Altamira Therapeutics Reports Additional Significant Efficacy Outcomes From Bentrio Clinical Trial In Seasonal Allergic Rhinitis
14/09/2023 14:17
Sept 14 (Reuters) - Altamira Therapeutics Ltd CYTO.O :
* ALTAMIRA THERAPEUTICS REPORTS ADDITIONAL SIGNIFICANT
EFFICACY
OUTCOMES FROM BENTRIO CLINICAL TRIAL IN SEASONAL ALLERGIC
RHINITIS
* ALTAMIRA THERAPEUTICS LTD - STUDY MEETS BOTH PRIMARY AND
SECONDARY EFFICACY ENDPOINTS
Source text for Eikon: ID:nGNX7dGJxm
Further company coverage: CYTO.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Altamira Therapeutics
See all newsBrief: Altamira Therapeutics Reports Full Year 2024 Results
Brief: Altamira Therapeutics Announces Transition From Nasdaq To OTC Markets
Brief: Altamira Therapeutics Provides Update On Nasdaq Listing
Brief: Altamira Therapeutics Provides Business Update And First Half 2024 Financial Results
Brief: Altamira Therapeutics Announces Pricing Of Up To $12.0 Mln Public Offering